



## Partner Profile

Crucell is a global biopharmaceutical company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, dedicated to bringing meaningful innovation to global health. Crucell focuses on the research & development, production and marketing of vaccines against infectious diseases worldwide.

**Website:** [www.crucell.com](http://www.crucell.com)

## Role in the ADVANCE Project

Crucell contributes to the establishment of best practices and code of conduct for benefit-risk monitoring of vaccines within WP1, to WP 4 to develop methods to identify burden of disease, vaccination coverage, vaccine safety & effectiveness, impact and benefit-risk monitoring, will participate to WP7 (Implementability Analysis and development of a blueprint) and is also involved in general project management and communication in WP 6.

## Key People

**Marc Ceuppens** has 19 years experience in the Pharmaceutical Industry, mostly in the area Pharmacovigilance. He is currently the Safety Head for Infectious Diseases and Vaccines (IDV) portfolio within the Global Medical Safety organization of the Janssen Pharmaceutical group (Based in Beerse, Belgium).

**Daniel Fife** is an epidemiologist trained in pediatrics. He serves as a Senior Director in Janssen's Epidemiology department, based in Titusville, New Jersey and has experience in public health and pharmacovigilance.

**Raphael Roten**, Swiss physician specialist in Pharmaceutical Medicine, joined Crucell Vaccines Pharmacovigilance in 2012. She serves as Medical Safety Officer within the Global Medical Safety Vaccines Group of the Janssen Pharmaceutical group.

---